Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20780304 | 0.93 | SLC6A2 (0.39) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL9288887 | 0.91 | SLC6A2 (0.38) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL19143811 | 0.89 | ADH1A (0.41) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL23733657 | 0.87 | SLC6A2 (0.43) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL20321803 | 0.86 | SLC6A2 (0.35) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL20321696 | 0.86 | SLC6A2 (0.35) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL12339309 | 0.85 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20321690 | 0.85 | PIK3CD (0.60) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL22813456 | 0.83 | SLC6A2 (0.34) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL22388253 | 0.82 | HRH3 (0.36) | SLC6A2SLC6A4PIK3CDSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | SLC6A2 4542/4885SLC6A4 4551/4885PIK3CD 406/4885 |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | SLC6A2 1782/4885SLC6A4 1287/4885PIK3CD 2884/4885 |
| US-20100323965-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | SLC6A2 4542/4885SLC6A4 4551/4885PIK3CD 406/4885 |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | SLC6A2 1380/4885SLC6A4 1399/4885PIK3CD 159/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | SLC6A2 1782/4885SLC6A4 1287/4885PIK3CD 2884/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | SLC6A2 1782/4885SLC6A4 1287/4885PIK3CD 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.